Ike S Okosun1, Francis Annor2, Ebenezer A Dawodu2, Michael P Eriksen2. 1. Division of Epidemiology & Biostatistics, School of Public Health, Georgia State University, Atlanta, GA 30302, United States. Electronic address: iokosun@gsu.edu. 2. Division of Epidemiology & Biostatistics, School of Public Health, Georgia State University, Atlanta, GA 30302, United States.
Abstract
AIM: To determine which cardiometabolic risk factors and clusters of cardiometabolic risk factors that are mostly associated with elevated HbA1c in non-Hispanic White (NHW), non-Hispanic Black (NHB) and Mexican-American (MA) adults who have type 2 diabetes. METHODS: Data (n=2910) from the United States National Health and Nutritional Examination Surveys were used in this study. Elevated HbA1c was defined as having HbA1c value was 7% or greater. Race/ethnicity-specific associations of individual and clustered (2-5 factors) cardiometabolic risk factors with elevated HbA1c were determined using prevalence odds ratio from multivariate logistic regression analyses. Statistical adjustments were made for sex, age, education, income and marital status. RESULTS: Joint occurrence of abdominal obesity, high blood pressure, and elevated triglycerides and joint occurrence of high blood pressure, elevated triglycerides and low HDL were more highly associated with elevated odds of HbA1c compared to other cardiometabolic risk factors joint occurrences. Joint occurrences of abdominal obesity, high blood pressure, and elevated triglycerides was associated with 2.3 (95% CI: 1.2-3.3), 9.1 (95% CI: 2.9-28.7) and 4.8 (95% CI: 2.0-11.5) increased odds of elevated HbA1c in NHW, NHB and MA, respectively. The corresponding values for the joint occurrence of high blood pressure, elevated triglycerides and low HDL was associated with 2.4 (95% CI: 1.2-3.7), 3.5 (95% CI: 1.1-5.5) and 2.6 (95% CI: 1.5-4.7) increased odds of elevated HbA1c in NHW, NHB and MA, respectively. CONCLUSION: This finding calls for consideration of cardiovascular risk factor clustering in deciding medical therapies to optimize glycemic control in individuals with type 2 diabetes. Interventions designed to achieve glycemic control coupled with modification of cardiometabolic risk factors may be crucial in alleviating sequelae resulting from type 2 diabetes.
AIM: To determine which cardiometabolic risk factors and clusters of cardiometabolic risk factors that are mostly associated with elevated HbA1c in non-Hispanic White (NHW), non-Hispanic Black (NHB) and Mexican-American (MA) adults who have type 2 diabetes. METHODS: Data (n=2910) from the United States National Health and Nutritional Examination Surveys were used in this study. Elevated HbA1c was defined as having HbA1c value was 7% or greater. Race/ethnicity-specific associations of individual and clustered (2-5 factors) cardiometabolic risk factors with elevated HbA1c were determined using prevalence odds ratio from multivariate logistic regression analyses. Statistical adjustments were made for sex, age, education, income and marital status. RESULTS: Joint occurrence of abdominal obesity, high blood pressure, and elevated triglycerides and joint occurrence of high blood pressure, elevated triglycerides and low HDL were more highly associated with elevated odds of HbA1c compared to other cardiometabolic risk factors joint occurrences. Joint occurrences of abdominal obesity, high blood pressure, and elevated triglycerides was associated with 2.3 (95% CI: 1.2-3.3), 9.1 (95% CI: 2.9-28.7) and 4.8 (95% CI: 2.0-11.5) increased odds of elevated HbA1c in NHW, NHB and MA, respectively. The corresponding values for the joint occurrence of high blood pressure, elevated triglycerides and low HDL was associated with 2.4 (95% CI: 1.2-3.7), 3.5 (95% CI: 1.1-5.5) and 2.6 (95% CI: 1.5-4.7) increased odds of elevated HbA1c in NHW, NHB and MA, respectively. CONCLUSION: This finding calls for consideration of cardiovascular risk factor clustering in deciding medical therapies to optimize glycemic control in individuals with type 2 diabetes. Interventions designed to achieve glycemic control coupled with modification of cardiometabolic risk factors may be crucial in alleviating sequelae resulting from type 2 diabetes.
Authors: Kathleen Dungan; Timothy E Craven; Kyaw Soe; Jackson T Wright; Jan Basile; William E Haley; Nancy R Kressin; Uzma Rani; Leonardo Tamariz; Jeff Whittle; Alan Wiggers; Kwame Osei Journal: Diabetes Obes Metab Date: 2017-11-09 Impact factor: 6.577
Authors: Viraj Raygor; Fahim Abbasi; Laura C Lazzeroni; Sun Kim; Erik Ingelsson; Gerald M Reaven; Joshua W Knowles Journal: Diab Vasc Dis Res Date: 2019-03 Impact factor: 3.291
Authors: Ahmed Hussein; Sharaf E D Mahmoud; Mohammad Shafiq Awad; Hossam Eldin M Mahmoud Journal: Diabetes Metab Syndr Obes Date: 2020-12-03 Impact factor: 3.168
Authors: C O Airhihenbuwa; J Iwelunmor; D Munodawafa; C L Ford; T Oni; C Agyemang; C Mota; O B Ikuomola; L Simbayi; M P Fallah; Z Qian; B Makinwa; C Niang; I Okosun Journal: Prev Chronic Dis Date: 2020-07-09 Impact factor: 2.830
Authors: Jun Jie Benjamin Seng; Amelia Yuting Monteiro; Yu Heng Kwan; Sueziani Binte Zainudin; Chuen Seng Tan; Julian Thumboo; Lian Leng Low Journal: BMC Med Res Methodol Date: 2021-03-11 Impact factor: 4.615
Authors: Miguel Marino; Heather Angier; Katie Fankhauser; Steele Valenzuela; Megan Hoopes; John Heintzman; Jennifer DeVoe; Laura Moreno; Nathalie Huguet Journal: Med Care Date: 2020-06 Impact factor: 3.178